About the Kirby Institute

The Kirby Institute is a leading global research institute dedicated to the prevention and treatment of infectious diseases.

We were established in 1986 in response to the then emerging 艾滋病 epidemic. We now contribute to knowledge on a broad range of diseases, including viral hepatitis and sexually transmissible infections. 

我们的 primary work relates to the coordination of national surveillance programs, population health and epidemiological research, clinical and behavioural research and clinical trials. 我们的研究 projects are conducted in partnership with communities most affected by epidemics. Together we implement trials of behavioural and biomedical interventions designed to prevent the spread of infectious diseases in vulnerable populations.

我们的 work in the laboratory is focused on finding ways to control infections, develop new therapies and ultimately towards the development of preventative vaccines. Outside of the laboratory, we provide critical leadership to decision makers in Australia and internationally on the most effective, efficient and sustainable strategies to address deadly epidemics.

我们的研究 has increasingly taken on a regional focus. Over the past two decades, we have developed collaborative programs in several countries that have involved training health workers and health researchers in the Asia Pacific region, advising governments on public health and clinical policy, informing international treatment guidelines and working to increase access to essential medicines. We have particularly strong partnerships in Thailand, Papua New Guinea, Indonesia, Myanmar, Fiji and the Solomon Islands.

我们的 world-class team comprises over 300 public health, clinical and laboratory scientists, research assistants, postgraduate students and professional staff.


Tony Kelleher
教授 Anthony (Tony) Kelleher is a clinician scientist who has been working in the field of HIV research and immunology for over 30 years. He is internationally renowned, having been involved with every 艾滋病 vaccine trail conducted in Australia as well as a number of phase I-IV clinical trials, especially those involving patients with primary infection. He has been with the Kirby Institute since 2001, serving as head of the Immunovirology and Pathogenesis Program since 2005. 教授 Kelleher was appointed 导向器 of the Kirby Institute in January 2019.


Michael Kirby
The Hon. Michael Kirby AC CMG 500 Internal Server Error

Internal Server Error

The server encountered an internal error and was unable to complete your request. Either the server is overloaded or there is an error in the application.

我们的 Founding 导向器 (1986–2018)

David Cooper
Scientia 教授 David Cooper AC FAA FAHMS was the inaugural director of the Kirby Institute. He passed away on 2018年3月18日 after a short illness. 教授 Cooper’s leadership in HIV research and treatment spanned more than three decades. His contributions were broad-ranging, covering basic, clinical and epidemiological research as well as membership on advisory groups to establish 艾滋病 treatment guidelines. He was a global advocate for regional engagement and capacity building for many years, particularly through clinical research.